|Polycystic kidney disease|
|Other names||Kidney - polycystic|
|Severely affected polycystic kidneys removed at time of transplantation|
|Types||ADPKD and ARPKD|
|Diagnostic method||MRI, CT scan, Ultrasound|
|Treatment||Antihypertensives, Life style management|
Polycystic kidney disease (PKD or PCKD, also known as polycystic kidney syndrome) is a genetic disorder in which the renal tubules become structurally abnormal, resulting in the development and growth of multiple cysts within the kidney. These cysts may begin to develop in utero, in infancy, in childhood, or in adulthood. Cysts are non-functioning tubules filled with fluid pumped into them, which range in size from microscopic to enormous, crushing adjacent normal tubules and eventually rendering them non-functional as well.
PKD is caused by abnormal genes that produce a specific abnormal protein; this protein has an adverse effect on tubule development. PKD is a general term for two types, each having their own pathology and genetic cause: autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). The abnormal gene exists in all cells in the body; as a result, cysts may occur in the liver, seminal vesicles, and pancreas. This genetic defect can also cause aortic root aneurysms, and aneurysms in the circle of Willis cerebral arteries, which if they rupture, can cause a subarachnoid hemorrhage.
Diagnosis may be suspected from one, some, or all of the following: new onset flank pain or red urine; a positive family history; palpation of enlarged kidneys on physical exam; an incidental finding on abdominal sonogram; or an incidental finding of abnormal kidney function on routine lab work (BUN, serum creatinine, or eGFR). Definitive diagnosis is made by abdominal CT exam.
Complications include hypertension due to the activation of the renin–angiotensin–aldosterone system (RAAS), frequent cyst infections, urinary bleeding, and declining renal function. Hypertension is treated with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Infections are treated with antibiotics. Declining renal function is treated with renal replacement therapy (RRT): dialysis and/or transplantation. Management from the time of the suspected or definitive diagnosis is by an appropriately trained doctor.
Signs and symptoms
Signs and symptoms include high blood pressure, headaches, abdominal pain, blood in the urine, and excessive urination. Other symptoms include pain in the back, and cyst formation (renal and other organs).
PKD is caused by abnormal genes which produce a specific abnormal protein which has an adverse effect on tubule development. PKD is a general term for two types, each having their own pathology and genetic cause: autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).
Autosomal dominant polycystic kidney disease (ADPKD) is the most common of all the inherited cystic kidney diseases with an incidence of 1:500 live births. Studies show that 10% of end-stage kidney disease (ESKD) patients being treated with dialysis in Europe and the U.S. were initially diagnosed and treated for ADPKD.
- Gene PKD1 is located on chromosome 16 and codes for a protein involved in regulation of cell cycle and intracellular calcium transport in epithelial cells, and is responsible for 85% of the cases of ADPKD.
- Gene PKD2 is identified, using genetic linkage study, on chromosome 4. A group of voltage-linked cation channels, with inward selectivity for K>Na>>Ca and outward selectivity for Ca2+ ≈ Ba2+ > Na+ ≈ K+, are coded for by PKD2 on chromosome 4.
- PKD3 recently appeared in research papers as a postulated third gene. Fewer than 10% of cases of ADPKD appear in non-ADPKD families. Cyst formation begins in utero from any point along the nephron, although fewer than 5% of nephrons are thought to be involved. As the cysts accumulate fluid, they enlarge, separate entirely from the nephron, compress the neighboring kidney parenchyma, and progressively compromise kidney function.
Autosomal recessive polycystic kidney disease (ARPKD) (OMIM #263200) is the less common of the two types of PKD, with an incidence of 1:20,000 live births and is typically identified in the first few weeks after birth. Unfortunately, the kidneys are often underdeveloped resulting in a 30% death rate in newborns with ARPKD. PKHD1 is involved.
Both autosomal dominant and autosomal recessive polycystic kidney disease cyst formation are tied to abnormal cilia-mediated signaling. The polycystin-1 and polycystin-2 proteins appear to be involved in both autosomal dominant and recessive polycystic kidney disease due to defects in both proteins. Both proteins have communication with calcium channel proteins, and causes reduction in resting (intracellular) calcium and endoplasmic reticulum storage of calcium.
The disease is characterized by a ‘second hit’ phenomenon, in which a mutated dominant allele is inherited from a parent, with cyst formation occurring only after the normal, wild-type gene sustains a subsequent second genetic ‘hit’, resulting in renal tubular cyst formation and disease progression.
PKD results from defects in the primary cilium, an immotile, hair-like cellular organelle present on the surface of most cells in the body, anchored in the cell body by the basal body. In the kidney, primary cilia have been found to be present on most cells of the nephron, projecting from the apical surface of the renal epithelium into the tubule lumen. The cilia were believed to bend in the urine flow, leading to changes in signalling, however this has since been shown to be an experimental error (the bending of cilia was an artifact of focal plane compensation, and also the actual effect on micturition by severe hypertension and cardiac arrest) and that bending of cilia does not contribute to alterations in Ca flux. While it is not known how defects in the primary cilium lead to cyst development, it is thought to possibly be related to disruption of one of the many signaling pathways regulated by the primary cilium, including intracellular calcium, Wnt/β-catenin, cyclic adenosine monophosphate (cAMP), or planar cell polarity (PCP). Function of the primary cilium is impaired, resulting in disruption of a number of intracellular signaling cascades which produce differentiation of cystic epithelium, increased cell division, increased apoptosis, and loss of resorptive capacity.
Polycystic kidney disease can be ascertained via a CT scan of abdomen, as well as, an MRI and ultrasound of the same area. A physical exam/test can reveal enlarged liver, heart murmurs and elevated blood pressure.
Most cases progress to bilateral disease in adulthood.
In 2018, Jynarque (Tolvaptan) was introduced  as the first FDA-approved treatment for PKD. In a recent long-term study, patients using Tolvaptan had a 6.4% higher kidney function after 5 years compared to standard of care. In 2019, a team of researchers at UCSB found that a ketogenic diet might be able to halt, or even reverse progression in mice, and the results of a first human case series study are showing potential benefit. The results of a 3-month randomized, prospective dietary intervention clinical trial are pending. In addition, recent research indicates that mild to moderate calorie restriction or time-restricted feeding  slow the progression of autosomal dominant polycystic kidney disease (ADPKD) in mice  Patient communities have been combining both ketogenic diets  and time-restricted feeding with a low-oxalate diet to prevent the formation of stones  and early reports show an average of 17% increase in kidney function after approximately one year on a ketogenic, time-restricted dietary regimen. If and when the disease progresses enough in a given case, the nephrologist or other practitioner and the patient will have to decide what form of renal replacement therapy will be used to treat end-stage kidney disease (kidney failure, typically stage 4 or 5 of chronic kidney disease).
That will either be some form of dialysis, which can be done at least two different ways at varying frequencies and durations (whether it is done at home or in the clinic depends on the method used and the patient's stability and training) and eventually, if they are eligible because of the nature and severity of their condition and if a suitable match can be found, unilateral or bilateral kidney transplantation.
A Cochrane Review study of autosomal dominant polycystic kidney disease made note of the fact that it is important at all times, while avoiding antibiotic resistance, to control infections of the cysts in the kidneys, and if affected, the liver, when needed for a certain duration to combat infection, by using, "bacteriostatic and bacteriocidal drugs".
ADPKD individuals might have a normal life; conversely, ARPKD can cause kidney dysfunction and can lead to kidney failure by the age of 40–60. ADPKD1 and ADPKD2 are very different, in that ADPKD2 is much milder.
Currently, there are no therapies proven effective to prevent the progression of ADPKD.
PKD is one of the most common hereditary diseases in the United States, affecting more than 600,000 people. It is the cause of nearly 10% of all end-stage renal disease. It equally affects men, women, and all races. PKD occurs in some animals as well as humans.
- "Polycystic kidney disease". MedlinePlus Medical Encyclopedia. Retrieved 2015-07-30.
- "Autosomal Dominant Polycystic Kidney Disease". National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Retrieved 3 January 2018.
- "Autosomal Recessive Polycystic Kidney Disease". National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Retrieved 3 January 2018.
- "What Is Polycystic Kidney Disease?". National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Retrieved 3 January 2018.
- Hildebrandt F (April 2010). "Genetic kidney diseases". Lancet. 375 (9722): 1287–1295. doi:10.1016/S0140-6736(10)60236-X. PMC 2898711. PMID 20382325.
- Kimberling WJ, Pieke-Dahl SA, Kumar S (November 1991). "The genetics of cystic diseases of the kidney". Seminars in Nephrology. 11 (6): 596–606. PMID 1767134.
- "polycystic kidney disease" at Dorland's Medical Dictionary
- Cramer MT, Guay-Woodford LM (July 2015). "Cystic kidney disease: a primer". Advances in Chronic Kidney Disease. 22 (4): 297–305. doi:10.1053/j.ackd.2015.04.001. PMID 26088074.
- "Polycystic Kidney Disease". www.niddk.nih.gov. Retrieved 2015-07-31.
- Porth C (2011-01-01). Essentials of Pathophysiology: Concepts of Altered Health States. Lippincott Williams & Wilkins. ISBN 9781582557243.
- Phua YL, Ho J (April 2015). "MicroRNAs in the pathogenesis of cystic kidney disease". Current Opinion in Pediatrics. 27 (2): 219–226. doi:10.1097/mop.0000000000000168. PMC 4409326. PMID 25490692.
- Bisceglia M, Galliani CA, Senger C, Stallone C, Sessa A (January 2006). "Renal cystic diseases: a review". Advances in Anatomic Pathology. 13 (1): 26–56. doi:10.1097/01.pap.0000201831.77472.d3. PMID 16462154. S2CID 12417947.
- Torres VE, Harris PC, Pirson Y (April 2007). "Autosomal dominant polycystic kidney disease". Lancet. 369 (9569): 1287–1301. doi:10.1016/S0140-6736(07)60601-1. PMID 17434405. S2CID 1700992.
- Simons M, Walz G (September 2006). "Polycystic kidney disease: cell division without a c(l)ue?". Kidney International. 70 (5): 854–864. doi:10.1038/sj.ki.5001534. PMID 16816842.
- Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, et al. (June 2016). "Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease". American Journal of Human Genetics. 98 (6): 1193–1207. doi:10.1016/j.ajhg.2016.05.004. PMC 4908191. PMID 27259053.
- Thivierge C, Kurbegovic A, Couillard M, Guillaume R, Coté O, Trudel M (February 2006). "Overexpression of PKD1 causes polycystic kidney disease". Molecular and Cellular Biology. 26 (4): 1538–1548. doi:10.1128/MCB.26.4.1538-1548.2006. PMC 1367205. PMID 16449663.
- Kumar S, Kimberling WJ, Gabow PA, Kenyon JB (June 1991). "Genetic linkage studies of autosomal dominant polycystic kidney disease: search for the second gene in a large Sicilian family". Human Genetics. 87 (2): 129–133. doi:10.1007/BF00204167. PMID 1676697. S2CID 22331271.
- Kumar S, Kimberling WJ, Gabow PA, Shugart YY, Pieke-Dahl S (November 1990). "Exclusion of autosomal dominant polycystic kidney disease type II (ADPKD2) from 160 cM of chromosome 1". Journal of Medical Genetics. 27 (11): 697–700. doi:10.1136/jmg.27.11.697. PMC 1017261. PMID 1980516.
- Kimberling WJ, Kumar S, Gabow PA, Kenyon JB, Connolly CJ, Somlo S (December 1993). "Autosomal dominant polycystic kidney disease: localization of the second gene to chromosome 4q13-q23". Genomics. 18 (3): 467–472. doi:10.1016/S0888-7543(11)80001-7. PMID 8307555.
- Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, et al. (May 1996). "PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein". Science. 272 (5266): 1339–1342. Bibcode:1996Sci...272.1339M. doi:10.1126/science.272.5266.1339. PMID 8650545. S2CID 28192819.
- Halvorson CR, Bremmer MS, Jacobs SC (2010-06-24). "Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment". International Journal of Nephrology and Renovascular Disease. 3: 69–83. doi:10.2147/ijnrd.s6939. PMC 3108786. PMID 21694932.
- Johnson RJ, Feehally J, Floege J (2014-09-05). Comprehensive Clinical Nephrology: Expert Consult - Online. Elsevier Health Sciences. ISBN 9780323242875.
- "Polycystic Kidney Disease". National Kidney Foundation. 2016-01-07. Retrieved 2022-11-17.
- "FDA Approves Tolvaptan for ADPKD". Kidney News. 10 (6). 2018-06-01. ISSN 1555-905X.
- Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, et al. (May 2022). "Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD". Kidney International Reports. 7 (5): 1037–1048. doi:10.1016/j.ekir.2022.02.009. PMC 9091612. PMID 35570988.
- Torres JA, Kruger SL, Broderick C, Amarlkhagva T, Agrawal S, Dodam JR, et al. (December 2019). "Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease". Cell Metabolism. 30 (6): 1007–1023.e5. doi:10.1016/j.cmet.2019.09.012. PMC 6904245. PMID 31631001.
- Strubl S, Oehm S, Torres JA, Grundmann F, Haratani J, Decker M, et al. (June 2022). "Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects". Clinical Kidney Journal. 15 (6): 1079–1092. doi:10.1093/ckj/sfab162. PMC 9155228. PMID 35664270.
- Müller R (2022-08-23). "Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)". University of Cologne.
- Nowak KL, Hopp K (April 2020). "Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential". Clinical Journal of the American Society of Nephrology. 15 (4): 577–584. doi:10.2215/CJN.13291019. PMC 7133124. PMID 32086281.
- Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, et al. (May 2016). "Food Restriction Ameliorates the Development of Polycystic Kidney Disease". Journal of the American Society of Nephrology. 27 (5): 1437–1447. doi:10.1681/ASN.2015020132. PMC 4849816. PMID 26538633.
- Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (April 2016). "A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease". American Journal of Physiology. Renal Physiology. 310 (8): F726–F731. doi:10.1152/ajprenal.00551.2015. PMC 4835927. PMID 26764208.
- Spencer S (2021-12-25). "6 Ways People with PKD Can Lower Their Blood Pressure". Medium. Retrieved 2022-10-24.
- Torres JA, Rezaei M, Broderick C, Lin L, Wang X, Hoppe B, et al. (July 2019). "Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease". The Journal of Clinical Investigation. 129 (10): 4506–4522. doi:10.1172/JCI128503. PMC 6763267. PMID 31361604.
- "Breakthrough Results After 7 Years of Reversing Pkd". 2022-10-20. Retrieved 2022-10-24.
- Montero N, Sans L, Webster AC, Pascual J (29 January 2014). "Interventions for infected cysts in people with autosomal dominant polycystic kidney disease". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd010946. S2CID 70649130.
- Torra R (2018-07-20). Talavera F, Aronoff GR (eds.). "Polycystic Kidney Disease: Practice Essentials, Background, Pathophysiology". Medscape.
- Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF (July 2015). "Interventions for preventing the progression of autosomal dominant polycystic kidney disease". The Cochrane Database of Systematic Reviews. 2015 (7): CD010294. doi:10.1002/14651858.CD010294.pub2. PMC 8406618. PMID 26171904.
- Tamparo C (2011). Fifth Edition: Diseases of the Human Body. Philadelphia, PA: F.A. Davis Company. p. 443. ISBN 978-0-8036-2505-1.
- "Polycystic kidney disease (PKD): Gene test and negative register". International Cat Care. Archived from the original on 17 November 2016. Retrieved 2 November 2014.
- "PKD - Polycystic Kidney Disease - British Shorthair". Antagene. Retrieved 2 November 2014.
- Chapin HC, Caplan MJ (November 2010). "The cell biology of polycystic kidney disease". The Journal of Cell Biology. 191 (4): 701–710. doi:10.1083/jcb.201006173. PMC 2983067. PMID 21079243.
- Harris PC, Torres VE (2009-01-01). "Polycystic kidney disease". Annual Review of Medicine. 60: 321–337. doi:10.1146/annurev.med.60.101707.125712. PMC 2834200. PMID 18947299.
- Halvorson CR, Bremmer MS, Jacobs SC (2010). "Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment". International Journal of Nephrology and Renovascular Disease. 3: 69–83. doi:10.2147/IJNRD.S6939. PMC 3108786. PMID 21694932.